{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:55:01Z","timestamp":1767192901920,"version":"3.44.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01310-z","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:04:50Z","timestamp":1758524690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Dual Therapy with HER2-inhibitors (Pertuzumab and Trastuzumab) in Gastric or Gastroesophageal Tumors: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0794-4605","authenticated-orcid":false,"given":"Geraldo Lucas Lopes","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3110-931X","authenticated-orcid":false,"given":"Jo\u00e3o Victor Ramos","family":"da Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-5190","authenticated-orcid":false,"given":"Jos\u00e9 Roberto","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7565-0724","authenticated-orcid":false,"given":"Saint Clair Vieira","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5934-8488","authenticated-orcid":false,"given":"Leticia Vieira","family":"dos Santos Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7305-4054","authenticated-orcid":false,"given":"Arthur Henrique","family":"Gohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-6010","authenticated-orcid":false,"given":"Daniella Serafin Couto","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"1310_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study. EClinMed. 2022;47:101404. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101404.","journal-title":"EClinMed"},{"issue":"3","key":"1310_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1310_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1470-2045(22)00704-5","volume":"24","author":"I Soerjomataram","year":"2023","unstructured":"Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol. 2023;24(1):22\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(22)00704-5.","journal-title":"Lancet Oncol"},{"key":"1310_CR4","unstructured":"WHO International Agency for Research on Cancer (2020) Cancer fact sheets: stomach cancer. GLOBOCAN 2020. Available from:\u00a0https:\/\/gco.iarc.who.int\/factsheets\/cancers\/stomach. Accessed 10 May 2025"},{"issue":"1","key":"1310_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-017-1132-5","volume":"15","author":"YY Lei","year":"2017","unstructured":"Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017;15(1):68. https:\/\/doi.org\/10.1186\/s12957-017-1132-5.","journal-title":"World J Surg Oncol"},{"key":"1310_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014: 852748. https:\/\/doi.org\/10.1155\/2014\/852748.","journal-title":"Mol Biol Int"},{"key":"1310_CR7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i19.4619","volume":"22","author":"LF Abrahao-Machado","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22:4619. https:\/\/doi.org\/10.3748\/wjg.v22.i19.4619.","journal-title":"World J Gastroenterol"},{"key":"1310_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103339","volume":"161","author":"K Egebjerg","year":"2021","unstructured":"Egebjerg K, Garbyal RS, Hasselby JP, Baeksgaard L, Mau-S\u00f8rensen M. Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;161: 103339. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103339.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1310_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/modpathol.3800712","volume":"20","author":"U Reichelt","year":"2007","unstructured":"Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120\u20139. https:\/\/doi.org\/10.1038\/modpathol.3800712.","journal-title":"Mod Pathol"},{"key":"1310_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3978\/j.issn.2078-6891.2013.039","volume":"5","author":"A Gowryshankar","year":"2014","unstructured":"Gowryshankar A, Nagaraja V, Eslick GD. HER2 status in Barrett\u2019s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol. 2014;5:25\u201335. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2013.039.","journal-title":"J Gastrointest Oncol"},{"key":"1310_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"1310_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1413513.","journal-title":"N Engl J Med"},{"issue":"4","key":"1310_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(18)30904-5.","journal-title":"Lancet Oncol"},{"key":"1310_CR14","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","volume":"27","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899\u2013903. https:\/\/doi.org\/10.1038\/s41591-021-01553-w.","journal-title":"Nat Med"},{"key":"1310_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/sjg.sjg_367_21","volume":"28","author":"YH Yan","year":"2022","unstructured":"Yan YH, Lei XY, Hu WP. Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: a network meta-analysis. Saudi J Gastroenterol. 2022;28:175\u201385. https:\/\/doi.org\/10.4103\/sjg.sjg_367_21.","journal-title":"Saudi J Gastroenterol"},{"key":"1310_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10120-022-01335-4","volume":"26","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Siddiqui A, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric\/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023;26:123\u201331. https:\/\/doi.org\/10.1007\/s10120-022-01335-4.","journal-title":"Gastric Cancer"},{"key":"1310_CR17","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, et al. FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol. 2022;40:3750\u201361. https:\/\/doi.org\/10.1200\/JCO.22.00380.","journal-title":"J Clin Oncol"},{"key":"1310_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1310_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1: 2. https:\/\/doi.org\/10.1186\/2046-4053-1-2.","journal-title":"Syst Rev"},{"key":"1310_CR20","unstructured":"Reuters T. EndNote\u00ae (version X7). Philadelphia: PA, USA; 2013."},{"key":"1310_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1310_CR22","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC (2019) Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from: www.training.cochrane.org\/handbook. Accessed 10 May 2025"},{"key":"1310_CR23","unstructured":"Sterne JAC, Higgins JPT et al (2024) Assessing The Risk Of Bias In Non-randomized Studies \u2013 of Interventions, Version 2 (ROBINS-I V2) assessment tool (for follow-up studies). https:\/\/www.riskofbias.info\/. Accessed 10 May 2025"},{"key":"1310_CR24","unstructured":"R Foundation for Statistical Computing (2025) R statistical software (version 4.2.3). Available from: https:\/\/www.R-project.org. Accessed 10 May 2025"},{"key":"1310_CR25","doi-asserted-by":"publisher","unstructured":"Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2-Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG). Oncol Res Treat. 2016;39:153\u2013154.https:\/\/doi.org\/10.1159\/000444702.","DOI":"10.1159\/000444702"},{"key":"1310_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1200\/JCO.19.01814","volume":"38","author":"CI Stroes","year":"2020","unstructured":"Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, et al. Phase II feasibility and biomarker study of neoadjuvant Trastuzumab and Pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study. J Clin Oncol. 2020;38:462\u201371. https:\/\/doi.org\/10.1200\/JCO.19.01814.","journal-title":"J Clin Oncol"},{"key":"1310_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521\u201330. https:\/\/doi.org\/10.1002\/cncr.11660.","journal-title":"Cancer"},{"issue":"11","key":"1310_CR28","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680\u20136.","journal-title":"Cancer"},{"issue":"7","key":"1310_CR29","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"M Shah","year":"2023","unstructured":"Shah M, Kennedy E, Alarcon-Rozas A, Alcindor T, Bartley A, Malowany A, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41(7):1470\u201391. https:\/\/doi.org\/10.1200\/JCO.22.02331.","journal-title":"J Clin Oncol"},{"key":"1310_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104617","author":"J Cai","year":"2025","unstructured":"Cai J, Wang W, Cong D, Bai Y, Zhang W. Development of treatment strategies for advanced HER2-positive gastric cancer: insights from clinical trials. Crit Rev Oncol Hematol. 2025. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104617.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1310_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"A Bartley","year":"2017","unstructured":"Bartley A, Washington M, Colasacco C, Ventura C, Ismaila N, Benson A, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(4):446\u201364. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836.","journal-title":"J Clin Oncol"},{"key":"1310_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00884-7","author":"B Grieb","year":"2021","unstructured":"Grieb B, Agarwal R. HER2-directed therapy in advanced gastric and gastroesophageal adenocarcinoma: triumphs and troubles. Curr Treat Options Oncol. 2021. https:\/\/doi.org\/10.1007\/s11864-021-00884-7.","journal-title":"Curr Treat Options Oncol"},{"key":"1310_CR33","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/1078-0432.CCR-10-2927","volume":"17","author":"Y Yamashita-Kashima","year":"2011","unstructured":"Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 2011;17:5060\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2927.","journal-title":"Clin Cancer Res"},{"issue":"Supp 8","key":"1310_CR34","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1158\/1538-7445.AM10-3477","volume":"70","author":"Y Yamashita","year":"2010","unstructured":"Yamashita Y, Yorozu K, Kurasawa M, Fujimoto-Ouchi K. Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers. Cancer Res. 2010;70(Supp 8):3477. https:\/\/doi.org\/10.1158\/1538-7445.AM10-3477.","journal-title":"Cancer Res"},{"key":"1310_CR35","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4597.","journal-title":"Cancer Res"},{"key":"1310_CR36","doi-asserted-by":"publisher","unstructured":"Liu T, Qin Y, Li J, Xu R, Xu J, Yang S, et al. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond) 2019;39:38. https:\/\/doi.org\/10.1186\/s40880-019-0384-6.","DOI":"10.1186\/s40880-019-0384-6"},{"key":"1310_CR37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/bjc.2014.356","volume":"111","author":"YK Kang","year":"2014","unstructured":"Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer. 2014;111:660\u20136. https:\/\/doi.org\/10.1038\/bjc.2014.356.","journal-title":"Br J Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01310-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:13:32Z","timestamp":1758719612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01310-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01310-z","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"27 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}